{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:36:20Z","timestamp":1761863780780},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET\/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET\/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET\/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.<\/jats:p>","DOI":"10.1097\/rlu.0000000000001934","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T03:00:02Z","timestamp":1513825202000},"page":"114-116","source":"Crossref","is-referenced-by-count":15,"title":["Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"43","author":[{"given":"Naghmehossadat","family":"Eshghi","sequence":"first","affiliation":[{"name":"From the *Departments of Medical Imaging and \u2020Medicine, Banner University Medical Center; and \u2021Department of Biomedical Engineering, University of Arizona, Tucson, AZ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara F.","family":"Lundeen","sequence":"additional","affiliation":[{"name":"From the *Departments of Medical Imaging and \u2020Medicine, Banner University Medical Center; and \u2021Department of Biomedical Engineering, University of Arizona, Tucson, AZ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip H.","family":"Kuo","sequence":"additional","affiliation":[{"name":"From the *Departments of Medical Imaging and \u2020Medicine, Banner University Medical Center; and \u2021Department of Biomedical Engineering, University of Arizona, Tucson, AZ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2214\/AJR.16.16532","article-title":"The value of FDG PET\/CT in treatment response assessment, follow-up, and surveillance of lung cancer","volume":"208","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.biopha.2013.11.002","article-title":"Performance of FDG PET\/ceCT in the evaluation of patients with lung cancer","volume":"68","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12957-016-0998-y","article-title":"FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer","volume":"14","year":"2016","journal-title":"World J Surg Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.3390\/diagnostics7020023","article-title":"Nuclear molecular imaging strategies in immune checkpoint inhibitor therapy","volume":"7","year":"2017","journal-title":"Diagnostics (Basel)"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s10147-016-0958-0","article-title":"Basics of PD-1 in self-tolerance, infection, and cancer immunity","volume":"21","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"bib6-20230925","first-page":"84","article-title":"Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients","volume":"20","year":"2016","journal-title":"J Immunother Cancer"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"e5951","DOI":"10.1097\/MD.0000000000005951","article-title":"Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab","volume":"96","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12032-017-0895-4","article-title":"Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence","volume":"34","year":"2017","journal-title":"Med Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201802000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:02:38Z","timestamp":1695618158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201802000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001934","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}